Business Wire

Teckro Expands Its Leadership Position in Clinical Trials With New Hires Malia Lewin and Silvina Baudino to Scale Its Global Market Strategy

20.5.2021 16:04:00 EEST | Business Wire | Press release

Share

Teckro, creator of the only clinical trials platform that facilitates collaboration and real-time decision-making between and among study stakeholders, today announces two key hires: Malia Lewin as global head of strategy and Silvina Baudino to lead the Teckro site strategy. They are the latest experienced veterans to join Teckro’s leadership team.

Other notable hires since the start of the year, include:

  • Former Veeva Systems sales leaders Ciaran Avitabile and Jeremy Schwarz join as Teckro global head and US head of sales, respectively;
  • Previous Salesforce solution engineering leader Brian Sharkey joins to build Teckro’s global solution consulting function;
  • Cheryl Murphy, with 20+ years of experience in the pharmaceutical industry, joins as Teckro VP of customer engagement and delivery where she will lead operational excellence for a world-class customer experience.

Malia Lewin to Lead Teckro’s Strategy for Optimal Market and Product Fit

Malia Lewin has nearly 20 years of experience in the biopharma industry, serving in a variety of roles to champion new ideas, innovation and technological advancements in life sciences. Most recently, Malia was chief business officer at CherryCircle Software, a maker of cloud-based software for pharmaceutical manufacturing. Among her other roles, she served as global director of oncology strategy at Veeva Systems.

Malia says, “While clinical research pushes forward incredible scientific advancements, the management of clinical trial operations is woefully behind. This creates friction that needlessly impacts the time and cost of delivering new treatments. Teckro’s platform changes the game by allowing a seamless flow of vital information between sites and sponsors. This enables faster, safer, more efficient trials and an improved path for life-saving treatments to people around the world. ”

Silvina Baudino to Champion Teckro Requirements for Sites’ Needs

Also joining Teckro’s strategy team, Silvina Baudino brings more than 20 years of clinical trial industry experience, most recently as director of strategic site networks for IQVIA. Her career has encompassed a diverse range of responsibilities, including building and implementing innovative site-centric delivery models as well as creating strategies to improve quality and accessibility to clinical trials for patients globally.

“While public awareness and appreciation for clinical research improved with the pandemic, research site staff are struggling to work through backlogs of trials that were put on hold or delayed due to COVID-19,” Silvina explains. “Teckro is uniquely positioned to help site staff manage their demanding workloads to deliver the best outcomes for patients and preserve the quality of the research data.”

CEO Gary Hughes reflects on the current strength of Teckro, saying: “The depth of the expertise of our leadership team is testament to the belief in Teckro’s mission and our positive impact on clinical trials operations. This all-star team of leaders gives confidence to the rest of our staff, prospective employees, and our customers that we can continue to modernize and simplify clinical operations and accelerate the pace of clinical research.

Watch this short Q&A with Malia and Silvina to hear their thoughts on joining Teckro on International Clinical Trials Day and how they believe the future of clinical trials will evolve.

About Teckro

Teckro’s cloud-based clinical trial platform connects research sites, monitors and study teams with access to critical information, real-time decision support, and vital insights into clinical operations and trial performance. Teckro is used at more than 20,000 research sites and by thousands of investigators around the world. The company works with six out of the top 10 pharmaceutical companies as well as emerging biotechs. A number of trials run on Teckro are now starting to report success metrics in meeting endpoints, and others have been granted priority review by regulators in the US and Europe.

More Information:

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Hannah Lippitt
hannah.lippitt@teckro.com
+44 7393334501

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye